drugset / Trial / NCT00231569

Dose-escalating Safety Study in Subjects on Stable Statin Therapy

NCT00231569

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of this study is to assess the safety of varying doses of ISIS 301012 in subjects on Stable statin therapy.

Timeline

Start
2005-09
Primary completion
2007-06
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject mipomersen Antisense oligonucleotide 30 mg Subcutaneous
Subject mipomersen Antisense oligonucleotide 100 mg Subcutaneous
Subject mipomersen Antisense oligonucleotide 200 mg Subcutaneous
Subject mipomersen Antisense oligonucleotide 300 mg Subcutaneous
Subject mipomersen Antisense oligonucleotide 400 mg Subcutaneous

Indications